Literature DB >> 2720677

Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells.

I L Dale1, T D Bradshaw, A Gescher, G R Pettit.   

Abstract

Activators of protein kinase C (PKC), such as 12-O-tetradecanoylphorbol-13-acetate (TPA) and bryostatins 1 and 2, inhibit the growth of A549 cells. At high concentrations the bryostatins do not affect cell growth. Here the hypothesis has been tested that modulation of A549 cell growth is the consequence of agent-induced changes in location or extent of cellular PKC activity. PKC activity was measured after semi-purification with nondenaturing polyacrylamide gel electrophoresis in the cytosol and the particulate fraction of A549 cells. When cells were exposed to TPA or mezerein, PKC activity underwent rapid and concentration-dependent translocation from the cytosol to the membrane. TPA at 0.1 microM or mezerein at 1 microM caused almost complete translocation within 30 min. Incubation with bryostatins 1 or 2 also led to enzyme translocation, which was, however, much weaker than that observed with the tumor promoters. Neither 4 alpha-phorboldidecanoate nor the synthetic diacylglycerols 1,2-sn-dioctanoylglycerol or 1-oleoyl-2-acetyl-sn-glycerol mimicked TPA in this way. Exposure of cells to TPA or the bryostatins for longer than 30 min caused the gradual disappearance of total cellular PKC activity. PKC downregulation was concentration dependent and complete after 24 h. A549 cells which had acquired temporary resistance toward the growth-arresting potential of TPA were completely devoid of any measurable PKC activity. The bryostatins were potent inhibitors of the binding of [3H]phorbol-12,13-dibutyrate to its receptors in intact cells, and the inhibition was dependent on bryostatin concentration. The results support the contention that PKC is involved in the mediation of growth inhibition caused by TPA or the bryostatins. However, the relationship between growth arrest and PKC translocation or downregulation seems to be a complex one.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2720677

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.

Authors:  A Monks; E D Harris; A Vaigro-Wolff; C D Hose; J W Connelly; E A Sausville
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

2.  Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1.

Authors:  Dan Zhao; Shereen Amria; Azim Hossain; Kumaran Sundaram; Peter Komlosi; Mitzi Nagarkatti; Azizul Haque
Journal:  Cell Immunol       Date:  2011-08-18       Impact factor: 4.868

3.  Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study.

Authors:  Robert J Morgan; Lucille Leong; Warren Chow; David Gandara; Paul Frankel; Agustin Garcia; Heinz-Josef Lenz; James H Doroshow
Journal:  Invest New Drugs       Date:  2010-10-09       Impact factor: 3.850

4.  Different biological effects of the two protein kinase C activators bryostatin-1 and TPA on human carcinoma cell lines.

Authors:  K G Steube; D Grunicke; H G Drexler
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

5.  Comparison of the antitumor activity of bryostatins 1, 5, and 8.

Authors:  A S Kraft; S Woodley; G R Pettit; F Gao; J C Coll; F Wagner
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

6.  Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors.

Authors:  Anna C Pavlick; Jennifer Wu; John Roberts; Mark A Rosenthal; Anne Hamilton; Scott Wadler; Kathleen Farrell; Michelle Carr; David Fry; Anthony J Murgo; Ruth Oratz; Howard Hochster; Leonard Liebes; Franco Muggia
Journal:  Cancer Chemother Pharmacol       Date:  2009-02-17       Impact factor: 3.333

7.  Involvement of the Ca(2+)-dependent phosphorylation of a 20 kDa protein in the proliferative effect of high-density lipoproteins (subclass 3) on the adenocarcinoma cell line A549.

Authors:  K A Tazi; M Bonnafous; G Favre; G Soula; F Le Gaillard
Journal:  Biochem J       Date:  1995-04-15       Impact factor: 3.857

Review 8.  Towards selective pharmacological modulation of protein kinase C--opportunities for the development of novel antineoplastic agents.

Authors:  A Gescher
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

Review 9.  Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer.

Authors:  Mohammad Mojtaba Sadeghi; Mohamed F Salama; Yusuf A Hannun
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

10.  Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation.

Authors:  C Courage; J Budworth; A Gescher
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.